18 Nov 2026, Wed

UnitedHealth Lost About $13B in Market Value. What CRUSH Threatens.

Medicare Advantage is not a side business for UnitedHealth. It is the architecture. So when a federal regulator proposes a rule that could recover roughly $9 billion per audit year from Medicare Advantage insurers, the question is not whether UnitedHealth has exposure. The question is how deep it runs.

UnitedHealth fell 5.42% to $389.68 on November 17, 2026, versus the Nasdaq Composite’s 0.74% decline that day. It fell harder than most managed care peers because it has the largest Medicare Advantage book, and extrapolated audits scale with enrollment.

What the CRUSH Rule Would Actually Do

The Comprehensive Regulations to Uncover Suspicious Healthcare proposal, known as CRUSH, would revise Medicare Advantage risk adjustment data validation (RADV) audit rules. In particular, it would codify extrapolation for improper payment recoveries beginning with payment year 2018 audits, and it would do so without applying a fee-for-service adjuster. Extrapolation lets CMS apply the error rate found in a sample of medical records to a plan’s entire contract population, rather than recovering only the overpayment tied to the enrollees actually reviewed. That is what turns a review of a few hundred charts into a contract-wide repayment demand.

CMS estimates the approach would recover about $9 billion per audit year on average, and CMS also projects nearly $90 billion in Federal budget savings from 2027 to 2036 from the quantified provisions of the proposed rule. That is the number markets reacted to. But the more instructive detail is the procedural history behind it.

Humana sued over the 2023 final RADV rule in September 2023, and a federal judge in Texas vacated that final rule on September 25, 2025, finding it was procedurally invalid under the Administrative Procedure Act. CRUSH would effectively re-propose elements of that vacated approach by applying extrapolated audit recoveries beginning with payment year 2018 audits, without applying the fee-for-service adjuster. CMS is essentially doing a procedural rerun, this time with notice and comment drafted to address the deficiency the court identified.

How Much of UnitedHealth’s Business Is at Stake

UnitedHealthcare Medicare and Retirement posted third-quarter 2026 revenues of $42.4 billion. Annualized, that segment alone approaches $170 billion. Premium revenues from CMS represented 44% of UnitedHealth Group’s total consolidated revenues for the year ended December 31, 2025, so Medicare Advantage rules weigh heavily on its results.

The earnings recovery UnitedHealth has built in 2026 makes the timing worse. Third-quarter 2026 revenues were $112.7 billion and earnings from operations were $6.6 billion, up from $4.3 billion a year earlier. That rebound is what investors were pricing. The CRUSH rule introduces a potentially retroactive liability that offsets part of that improved outlook before the company has modeled it publicly.

Bull Case, Bear Case

The bull argument starts with process. CRUSH is a proposed rule released November 16, 2026. The Federal Register publication is scheduled for November 19, 2026, and the comment deadline is 60 days after publication. CMS has also stated that comments can be submitted until January 19, 2027. From comment close to a final rule to an effective date, the industry has time to litigate and lobby. The earlier RADV rule spent years in court before it was vacated. This one will face the same gauntlet.

The bear case is that CMS has explicitly addressed the procedural flaw the court found. CRUSH is a standalone, discretionary program integrity rule, and CMS says it intends to issue program integrity rulemaking of this kind on an annual basis going forward. That signals institutional resolve, not a one-off. The key question is how aggressively CMS uses its RADV audit authority once the framework is finalized.

What Investors Should Watch

Three things matter most from here. First, whether CMS’s Fifth Circuit appeal in the Humana case succeeds alongside or instead of the CRUSH rulemaking. Second, whether UnitedHealth management quantifies RADV exposure on its next earnings call rather than deferring. Third, whether the comment period produces legal arguments strong enough to delay or reshape the final rule.

The managed care sector has beaten back aggressive RADV proposals before. But each prior fight started from a weaker regulatory posture than this one. CMS has now watched a rule die in court, studied why, and filed a replacement that addresses the procedural issue in the document itself. That is a different opponent than the one UnitedHealth faced in 2023.

At $389, UNH trades at a steep discount to where it opened the week. The question is whether the discount reflects the actual liability or just the headline. Until management sizes the exposure, that answer belongs to anyone’s guess.